Studies on experimental models of non-alcoholic fatty liver disease (NAFLD) have revealed a potential dual role of leptin in NAFLD, which may have anti-lipogenic effects as well as pro-inflammatory and pro-fibrogenic actions [100]. Here, LEP is linked to metabolic dysfunction-associated steatotic liver disease.